Characterization of long-term responders following treatment with   talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the   phase 3 embraca trial.

Dokumenttyp:: Meeting Abstract
Autor(en):: Ettl, Johannes; Rugo, Hope S.; Hurvitz, Sara A.; Martin, Miguel; Roche, Henri; Lee, Kyung-Hun; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Guenzel, Carolin; Blum, Joanne Lorraine; Litton, Jennifer Keating
Titel:: Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2021
Band / Volume:: 39 Suppl S
Heft / Issue:: 15
Volltext / DOI:: doi:10.1200/JCO.2021.39.15_suppl.1029
Print-ISSN:: 0732-183X
TUM Einrichtung:: Frauenklinik und Poliklinik
BibTeX

Vorkommen: